ReviewCurrent psychiatry reports2024
Using Cannabis and CBD to Sleep: An Updated Review.
Review in Current psychiatry reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial.Journal of sleep research · 2026Trial
- Cannabis-Based Medicinal Products for Endometriosis: A 2-Year Prospective Analysis From the UK Medical Cannabis Registry.The Australian & New Zealand journal of obstetrics & gynaecology · 2026Observational
- Article
- Nicotine and Cannabis Co-Use and Sleep-Related Outcomes in Adults: A Narrative Review and Implications.Current addiction reports · 2026Article
- Cannabis use frequency may differentially impact cognitive performance in young adults with and without HIV.Frontiers in adolescent medicine · 2026Article
- Unraveling Cannabidiol's Bidirectional Regulation of Melatonin Pharmacokinetics via PEPT1/CYP1A2: Mechanistic Insights and Quantitative Projections.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Assessing patient perceptions of off-label cannabidiol use for insomnia through sentiment analysis.Journal of cannabis research · 2025Article
- The use of cannabinoid therapy in treatment-refractory isolated REM sleep behavior disorder: a case report.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cannabidiol (CBD) and cognitive function in older adults: a mini review.Frontiers in psychiatry · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
purpose of reviewCannabis sativa and constituent cannabinoids are in widespread use for the treatment of sleep disorders where many patients desire pharmacotherapy. Previous reviews highlight a lack of high-quality evidence to support the efficacy and long-term safety of cannabinoids in various conditions. We aim to provide an update of recent original research evaluating cannabinoid-based therapeutics in sleep disorders. RECENT
findingsWe identified twenty-one recent studies of cannabinoids for insomnia, subjective sleep impairment, obstructive sleep apnoea, rapid eye movement sleep behaviour disorder, and restless legs syndrome. We note trends towards the use of minor cannabinoids, studies using decentralised approaches and increased utilisation of objective measures in clinical trials. The evidence-base does not match widespread use of cannabinoids for the treatment of sleep disorders. There is a growing need for adequately funded well-designed clinical trials with longer treatment durations and decent sample sizes to inform both the clinician and patient.
Indexed as
Identifiers
39612156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.